# Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma

Source: https://onco.cc/key-papers/paper-gerami-melanoma-gene-expression-profile-clin-cancer-res-2015/  
OnCo record `paper-gerami-melanoma-gene-expression-profile-clin-cancer-res-2015` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The development of a gene-activity signature for skin melanoma that separated patients with a low and high chance of the cancer coming back.

## Summary

A 28-gene signature (with control genes, the basis of the 31-gene test) classified primary melanomas; disease-free survival in the validation set was 97 per cent for class 1 and 31 per cent for class 2.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: Clinical Cancer Research
- Year: 2015
- DOI: 10.1158/1078-0432.CCR-13-3316
- Authors: Gerami P, Cook RW, Wilkinson J, et al.
- Findings: Validation disease-free survival 97% (class 1) and 31% (class 2).
- What it means: Gene activity in the primary melanoma adds risk information to stage.
- Caveats: Retrospective archival samples.

## Sources

- Gerami et al., Clin Cancer Res 2015: https://doi.org/10.1158/1078-0432.CCR-13-3316
- PubMed: https://pubmed.ncbi.nlm.nih.gov/25564571/

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/)
- drugs: [DecisionDx-Melanoma](https://onco.cc/drugs/decisiondx-melanoma/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-gerami-melanoma-gene-expression-profile-clin-cancer-res-2015.json